Precision oligonucleotides for therapeutics

Antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) play key roles in gene modulation strategies. ASOs are single-stranded oligonucleotides that hybridise with target RNA sequences via complementary base pairing, inducing RNase H-mediated degradation or steric blocking of translation. In contrast, siRNAs are double-stranded molecules that integrate into the RNA-induced silencing complex (RISC) to degrade complementary mRNA sequences. Both approaches offer targeted gene silencing, making them promising tools for treating genetic disorders, viral infections, and oncological indications. The therapeutic potential of these novel long-lasting or even curative treatment approaches is underscored by the market approval of eleven ASOs and six siRNAs as drugs to date.

Tailored Solutions for Success
Microsynth’s therapeutic oligo services are designed to meet the specific needs of each project. Key features include:

Expert design support: Our experienced team helps optimise sequences for stability, potency, and specificity. Through close collaboration with researchers, we provide customer-centric guidance on sequence design, chemical modifications, and project-specific requirements.
Flexible production scales: Oligonucleotides are available from low nanomole quantities for initial screening to batch sizes up to 2000 mg for in vivo studies, enabling seamless scalability as projects progress.

Wide modification options: A broad selection of modifications is offered, including GalNAc, cholesterol, 2’-MOE, LNA, PTO, and custom lipid conjugates. These options enable researchers to optimise their molecules for enhanced cellular uptake, increased stability, and improved pharmacokinetics.

Advanced purification & QC: RP/IEX-HPLC purification, MALDI-TOF/ESI-MS, and rigorous endotoxin testing ensure the highest quality, giving researchers confidence in their results.

Regulatory compliance: Microsynth holds ISO 9001:2015 and ISO 13485:2016 certifications, ensuring reliability and reproducibility.
Rapid turnaround times: As short as three to four working days for screening oligos and five to six days for scale-up batches, accelerating timelines without compromising quality.

Trusted Partner in Therapeutics
At Microsynth, we recognise that success is built on more than just delivering high-quality oligonucleotides – it’s about fostering strong partnerships with our customers. Our philosophy goes beyond transactions; we are committed to understanding your unique challenges and providing tailored support at every stage of development. By prioritising collaboration, flexibility, and scientific excellence, we ensure that our solutions align with customer goals, helping them turn innovation into real therapeutic impact.

Contact Microsynth today to discover how the team can accelerate custom therapeutic oligonucleotide development with precision and reliability.

Microsynth AG
Schützenstr. 15
CH-9436 Balgach
Phone: +41 71 722 83 33
info@microsynth.ch

This article from Elges Lardi, Business Development Therapeutic Oligonucleotides, Microsynth AG, was originally published in the Special in European Biotechnology Magazine Spring 2025.